These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 28421352)

  • 1. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
    Shalash AO; Elsayed MMA
    AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.
    Elsayed MMA; Alfagih IM; Brockbank K; Aodah AH; Ali R; Almansour K; Shalash AO
    Int J Pharm; 2024 Apr; 655():123966. PubMed ID: 38452834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine excipient materials in carrier-based dry powder inhalation formulations: The interplay of particle size and concentration effects.
    Elsayed MMA; Alfagih IM; Brockbank K; Alheibshy F; Aodah AH; Ali R; Almansour K; Shalash AO
    Int J Pharm X; 2024 Jun; 7():100251. PubMed ID: 38799178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Roughness on the Dispersion of Dry Powders for Inhalation: a Dynamic Visualization Perspective.
    Kou X; Heng PWS; Chan LW; Wereley ST; Carvajal MT
    AAPS PharmSciTech; 2019 Jul; 20(7):271. PubMed ID: 31363868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
    Thalberg K; Åslund S; Skogevall M; Andersson P
    Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the potential of rheological measurements in development of dry powder inhalation formulations.
    Almansour K; Alfagih IM; Shalash AO; Brockbank K; Ali R; Freeman T; Elsayed MMA
    Int J Pharm; 2022 Feb; 614():121407. PubMed ID: 34942326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
    Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
    Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
    Zeng XM; Pandhal KH; Martin GP
    Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
    Shalash AO; Khalafallah NM; Molokhia AM; Elsayed MMA
    AAPS PharmSciTech; 2018 Feb; 19(2):912-922. PubMed ID: 29063377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.